Since June 6, the vaccine has been 64 percent effective at preventing infection and symptomatic disease and 93 percent effective in preventing serious illness in Israel.
Earlier studies from the Israeli government said Pfizer’s vaccine was 94 percent effective at preventing COVID-19 and 97 percent effective at preventing severe illness. The new figures represent a drop in the vaccine’s efficacy rate as the delta coronavirus variant spreads across the country and world, according to Bloomberg.
The time period the researchers studied also coincided with the Israeli government’s lifting of social distancing requirements.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.